Update of ICT-107 Glioblastoma Clinical Trial: I C Great Potential In Dendritic Cell Therapies.

We originally posted the results from the ICT-107 Glioblastoma (GBM) Clinical Trial back in September 29, 2011 and marked it as a potential game changer in treatment of brain tumors.

In short, ICT-107 is a vaccine based on dendritic cells, which are a type of cell that presents an antigen to other immune cells so that they can seek out and destroy the foreign cells that express the particular antigen.

ICT-107 is derived from a patient’s white blood cells via blood and the cells are then cultured with 6 tumor antigens common to glioblastomas. These “new” dendritic cells are then injected under the patient’s skin, where they seek out and destroy lingering tumor cells.

In a recent update from this study;

  • 7 of the 16 participants are still alive living, with length of survival ranging from 60.7 to 82.7 months after diagnosis.
  • 6 of the patients also were “progression free” for more than 5 yrs, meaning the tumors did not return or require more treatment during that time.
  • 4 participants still remain free of disease with good quality of life at lengths ranging from 65.1 to 82.7 months following diagnosis.

It is important to note that these patients all had tumors with at least 4 out of the 6 antigens used to prime the dendritic cells.

With the standard care for GBM, the median length of survival is typically only 15 months after diagnosis and only 10 % survive more than 5 years.

I like this approach because it is non-invasive, targets only the tumor cells, and provides further evidence as to the efficacy of targeted therapies when the appropriate antigen targets are used.

I can only imagine the impact on patient survival if this approach was combined with advanced surgical techniques such as “the brain path” approach developed by NICO Corporation.

Update: 50 Percent of Patients in Cedars-Sinai Brain Cancer Study Alive After Five Years

Speak Your Mind